Co-Authors
This is a "connection" page, showing publications co-authored by RONY AVRITSCHER and ARMEEN MAHVASH.
Connection Strength
1.325
-
Temporary Reversal of Hepatoenteric Collaterals during 90Y Radioembolization Planning and Administration. Curr Oncol. 2022 12 06; 29(12):9582-9592.
Score: 0.224
-
A Prospective Phase II Study of Safety and Efficacy of Sorafenib Followed by 90Y Glass Microspheres for Patients with Advanced or Metastatic Hepatocellular Carcinoma. J Hepatocell Carcinoma. 2021; 8:1129-1145.
Score: 0.205
-
Why bundled payments could drive innovation: an example from interventional oncology. J Oncol Pract. 2015 Mar; 11(2):e199-205.
Score: 0.130
-
Gastroduodenal artery recanalization after transcatheter fibered coil embolization for prevention of hepaticoenteric flow: incidence and predisposing technical factors in 142 patients. Acta Radiol. 2013 Sep; 54(7):790-4.
Score: 0.115
-
Temporary balloon occlusion of the common hepatic artery for yttrium-90 glass microspheres administration in a patient with hepatocellular cancer and renal insufficiency. Case Rep Radiol. 2013; 2013:560758.
Score: 0.115
-
Temporary balloon occlusion of the common hepatic artery for administration of yttrium-90 resin microspheres in a patient with patent hepatoenteric collaterals. J Vasc Interv Radiol. 2012 Feb; 23(2):277-80.
Score: 0.106
-
Salvage Locoregional Therapy Following Progression After Radiotherapy for Hepatocellular Carcinoma Is Associated with Improved Outcomes. J Gastrointest Surg. 2023 09; 27(9):1867-1875.
Score: 0.058
-
A novel method for predicting hepatocellular carcinoma response to chemoembolization using an intraprocedural CT hepatic arteriography-based enhancement mapping: a proof-of-concept analysis. Eur Radiol Exp. 2023 01 30; 7(1):4.
Score: 0.057
-
Disease control and failure patterns of unresectable hepatocellular carcinoma following transarterial radioembolization with yttrium-90 microspheres and with/without sorafenib. World J Gastroenterol. 2021 Dec 21; 27(47):8166-8181.
Score: 0.052
-
Survival Outcomes for Yttrium-90 Transarterial Radioembolization With and Without Sorafenib for Unresectable Hepatocellular Carcinoma Patients. J Hepatocell Carcinoma. 2020; 7:117-131.
Score: 0.048
-
Natural History of T1N0M0 Hepatocellular Carcinoma: Large-Scale Study in the United States. Oncology. 2017; 93(4):233-242.
Score: 0.038
-
Efficacy of a Self-expanding Tract Sealant Device in the Reduction of Pneumothorax and Chest Tube Placement Rates After Percutaneous Lung Biopsy: A Matched Controlled Study Using Propensity Score Analysis. Cardiovasc Intervent Radiol. 2017 Feb; 40(2):270-276.
Score: 0.037
-
Minimally invasive image-guided therapies for hepatocellular carcinoma. J Hepatocell Carcinoma. 2016; 3:55-61.
Score: 0.037
-
Multiple Renal Artery Pseudoaneurysms in Patients Undergoing Renal Artery Embolization Following Partial Nephrectomy: Correlation with RENAL Nephrometry Scores. Cardiovasc Intervent Radiol. 2017 Feb; 40(2):202-209.
Score: 0.036
-
Balloon-Assisted Flow Diversion and Selective Catheterization of Target Vessels for Hepatic Transarterial Embolization. J Vasc Interv Radiol. 2016 Feb; 27(2):283-5.
Score: 0.035
-
The Effect of Needle Gauge on the Risk of Pneumothorax and Chest Tube Placement After Percutaneous Computed Tomographic (CT)-Guided Lung Biopsy. Cardiovasc Intervent Radiol. 2015 Dec; 38(6):1595-602.
Score: 0.033